Business & Finance
Business and Finance
Business and Finance 
Mon, December 21, 2009
Medipattern Continues National Roll-Out With its 150th B-CAD(R) License at Weinstein Imaging in Pennsylvania
TORONTO, ONTARIO--(Marketwire - Dec. 21, 2009) -
Attention: Business/Financial Editors
The Medipattern Corporation ("Medipattern") (TSX VENTURE:MKI), a pioneer in the development of medical software solutions that help improve imaging workflow and productivity, announced today that its 150th B-CAD® license was installed at Weinstein Imaging Associates in Pittsburgh, Pennsylvania. Medipattern's B-CAD® computer-aided detection (CAD) helps physicians to assess breast lesions, increasing accuracy through standardized reporting and the use of the American College of Radiology BI-RADS® (Breast Imaging-Reporting and Data System) lexicon. B-CAD is available through three different sales models. Customers may purchase, lease or they may gain the value of B-CAD through the managed service plan called B-CAD-FOR-LIFETM; where they pay one monthly fee for the service. The total B-CAD license count includes a mix of purchased, leased and managed service units.
"Weinstein Imaging Associates has been committed to providing leading edge imaging services since 1980. We are fortunate to have a dedicated group of medical professionals focused on quality patient care. When we first saw B-CAD, we readily understood how it would improve our practice through standardization. B-CAD puts everyone in the practice, from our ultrasound technologists to our physicians, on the same page using the same terms. Our reporting is enriched by computer-aided detection which helps us to characterize lesions," commented Marcela Bohm-Velez, MD, FACR, FSRU, FAIUM, President of Weinstein Imaging Associates and Clinical Assistant Professor for the Radiology Dept. University of Pittsburgh. "As Weinstein Imaging continues to grow, we never lose sight of our most important mission - providing enhanced patient care through advanced imaging technology. B-CAD helps us to achieve this goal."
"Weinstein Imaging Associates is the first B-CAD site in Pennsylvania, further expanding Medipattern's national roll out," stated Jeff Collins, CEO of The Medipattern Corporation. "Weinstein Imaging Associates consistently brings innovative technology to its community. The practice was early to offer advanced breast imaging services using breast MRI, molecular breast imaging / breast specific gamma imaging, and now B-CAD computer aided detection for breast ultrasound. They specifically focus on providing outstanding breast care. Dr. Bohm-Velez is an active advocate for improved breast care. She is a current member of the Ultrasound BI-RADS committee, ACR Ultrasound Commission, ACR Ultrasound Guidelines Committee, ACR Ultrasound Economics Committee, ACR Foundation International Outreach Committee, and the Society of Radiologists in Ultrasound Program Committee. In the past, she served as the president of the Pennsylvania Radiological Society and is a former member of the ACR Council Steering Committee. It is an honor to consider her and her entire staff as part of the B-CAD family. Their daily use of B-CAD is an affirmation of the value that B-CAD provides."
About The Medipattern Corporation:
Medipattern® (TSX VENTURE:MKI) is a pioneer in the development of medical software solutions that help improve imaging workflow and productivity. Our first-to-market, award-winning B-CAD® advances breast ultrasound computer aided detection (CAD) by streamlining workflow and organizing information into a comprehensive patient record. Medipattern uses its CadenzaTM CAD Technology to power the digital conversion in medical communications. B-CAD automatically creates fully digital standardized worksheets and reports that make every practice more efficient, productive and ultimately more effective. For more information, please visit the Company's website at: [ www.medipattern.com ].
B-CAD® and Medipattern® are registered marks and CadenzaTM is a trademark of The Medipattern Corporation.
Forward-looking statements
This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates,'' "believes,'' "estimates,'' "expects,'' "plans,'' "intends,'' "potential'', and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at [ www.sedar.com ]). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.
The TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.